Results 191 to 200 of about 154,650 (346)

BMI1 Overexpression Alleviates Metabolic Syndrome‐Related Liver Injury by Inhibiting the Activation of the METTL3/AHNAK Axis

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Abnormal protein levels have been demonstrated to contribute to the progression of various diseases, including metabolic syndrome (MetS). Here, we speculated that the downregulation of BMI1 might lead to the failure of METTL3 degradation and contribute to METTL3 overexpression in MetS‐related liver injury.
Yun‐Jiang Chen   +4 more
wiley   +1 more source

Tirzepatide use in adolescents with metabolic dysfunction‐associated steatotic liver disease (MASLD): A case series [PDF]

open access: yesJPGN Rep
Abstract Pediatric obesity and metabolic dysfunction‐associated steatotic liver disease (MASLD) prevalence has risen markedly over the past decade. Due to transition delays and workforce shortages, pediatric specialists often manage patients into young adulthood, and thus familiarity with adult pharmacotherapies for MASLD is essential.
Perumpail B, Tou A, Panganiban J.
europepmc   +2 more sources

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

open access: yesThe Lancet, 2019
Z. Younossi   +34 more
semanticscholar   +1 more source

TRIB3 Is a Hub Gene in Steatohepatitis and Aggravates Lipid Deposition and Inflammation in Hepatocytes

open access: yesDiabetes, Metabolic Syndrome and Obesity
Wen Xia,1,* Li Xiao,1,* Huan Cheng,1 Yuwei Feng2 1Department of Cardiovascular Medicine, Wuhan No.1 Hospital, Wuhan, Hubei, People’s Republic of China; 2Department of Hepatology with Integrated Traditional Chinese and Western Medicine, Hubei No.3
Xia W, Xiao L, Cheng H, Feng Y
doaj  

Gene primers for metabolic-associated steatohepatitis

open access: yes
Gene primers of human and mouse for metabolic-associated steatohepatitis, which encompass genes associated with lipid synthesis, fatty acid oxidation, inflammation, and hepatic ...
Wang, lulu
core   +1 more source

Toxicity Differences Between Microplastics and Nanoplastics in Organs: From Molecular Mechanisms to Potential Therapeutic Strategies

open access: yesMed Research, EarlyView.
This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy